Molecular imaging of inflammation in atherosclerosis

Theranostics

Volumn 3, Issue 11, 2013, Pages 865-884

  Wildgruber, Moritz ^a   Swirski, Filip K ^b   Zernecke, Alma ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c German Center for Cardiovascular Research   (Germany)

Author keywords

Atherosclerosis; Inflammation; Molecular imaging

Indexed keywords

GADOLINIUM; GOLD NANOPARTICLE; NANOROD; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; BIOLOGICAL MARKER;

APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD VESSEL CALCIFICATION; CARDIAC IMAGING; CELL ACTIVATION; CELL INFILTRATION; CELL MEMBRANE PERMEABILITY; CELL METABOLISM; CELL PHAGOCYTOSIS; CELL TRANSPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; ECHOGRAPHY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FLUORESCENCE IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOCOMPETENT CELL; INFLAMMATION; LIPID OXIDATION; LIPID STORAGE; MOLECULAR IMAGING; MONOCYTE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PARTICLE SIZE; PHOTOACOUSTICS; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEGRADATION; RADIATION EXPOSURE; REVIEW; SHEAR STRESS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; METHODOLOGY; PATHOLOGY;

ATHEROSCLEROSIS; INFLAMMATION; MOLECULAR IMAGING;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; MOLECULAR IMAGING;

EID: 84904376928     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5771     Document Type: Review

References (183)

1. Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. European heart journal. 2012; 33: 1309-17. doi:10.1093/eurheartj/ehs067.
2. Pelisek J, Eckstein HH, Zernecke A. Pathophysiological mechanisms of carotid plaque vulnerability: impact on ischemic stroke. Archivum immunologiae et therapiae experimentalis. 2012; 60: 431-42. doi:10.1007/s00005-012-0192-z.
3. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature medicine. 2011; 17: 1410-22. doi:10.1038/nm.2538.
4. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature reviews Immunology. 2008; 8: 802-15. doi:10.1038/nri2415.
5. Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circulation research. 2011; 108: 593-606. doi:10.1161/CIRCRESAHA.110.232678.
6. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circulation research. 2012; 111: 231-44. doi:10.1161/CIRCRESAHA.112.268144.
7. Kajander S, Joutsiniemi E, Saraste M, Pietila M, Ukkonen H, Saraste A, et al. Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. Circulation. 2010; 122: 603-13. doi:10.1161/CIRCULATIONAHA.109.915009.
8. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovascular pathology. 2004; 13: 125-38. doi:10.1016/S1054-8807(04)00004-3.
9. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation. 2003; 107: 2072-5. doi:10.1161/01.CIR.0000069329.70061.68.
10. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003; 108: 1772-8. doi:10.1161/01.CIR.0000087481.55887.C9.
11. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003; 108: 1664-72. doi:10.1161/01.CIR.0000087480.94275.97.
12. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nature medicine. 2007; 13: 636-41. doi:10.1038/nm1571.
13. Luo T, Huang P, Gao G, Shen G, Fu S, Cui D, et al. Mesoporous silica-coated gold nanorods with embedded indocyanine green for dual mode X-ray CT and NIR fluorescence imaging. Optics express. 2011; 19: 17030-9. doi:10.1364/OE.19.017030.
14. Sun H, Yuan Q, Zhang B, Ai K, Zhang P, Lu L. Gd(III) functionalized gold nanorods for multimodal imaging applications. Nanoscale. 2011; 3: 1990-6. doi:10.1039/c0nr00929f.
15. Xiao Y, Hong H, Matson VZ, Javadi A, Xu W, Yang Y, et al. Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. Theranostics. 2012; 2: 757-68. doi:10.7150/thno.4756.
16. Esposito L, Saam T, Heider P, Bockelbrink A, Pelisek J, Sepp D, et al. MRI plaque imaging reveals high-risk carotid plaques especially in diabetic patients irrespective of the degree of stenosis. BMC medical imaging. 2010; 10: doi:10.1186/1471-2342-10-27.
17. Saam T, Underhill HR, Chu B, Takaya N, Cai J, Polissar NL, et al. Prevalence of American Heart Association type VI carotid atherosclerotic lesions identified by magnetic resonance imaging for different levels of stenosis as measured by duplex ultrasound. Journal of the American College of Cardiology. 2008; 51: 1014-21. doi:10.1016/j.jacc.2007.10.054.
18. Burtea C, Laurent S, Vander Elst L, Muller RN. Contrast agents: magnetic resonance. Handbook of experimental pharmacology. 2008;: 135-65. doi:10.1007/978-3-540-72718-7_7.
19. Hyafil F, Laissy JP, Mazighi M, Tchetche D, Louedec L, Adle-Biassette H, et al. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26: 176-81. doi:10.1161/01.ATV.0000194098.82677.57.
20. Korosoglou G, Weiss RG, Kedziorek DA, Walczak P, Gilson WD, Schar M, et al. Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using "positive contrast" magnetic resonance imaging. Journal of the American College of Cardiology. 2008; 52: 483-91. doi:10.1016/j.jacc.2008.03.063.
21. Morishige K, Kacher DF, Libby P, Josephson L, Ganz P, Weissleder R, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation. 2010; 122: 1707-15. doi:10.1161/CIRCULATIONAHA.109.891804.
22. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001; 103: 415-22.
23. Trivedi RA, JM UK-I, Graves MJ, Cross JJ, Horsley J, Goddard MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke, a journal of cerebral circulation. 2004; 35: 1631-5. doi:10.1161/01.STR.0000131268.50418.b7.
24. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 961-6. doi:10.1073/pnas.0606281104.
25. den Adel B, van der Graaf LM, Que I, Strijkers GJ, Lowik CW, Poelmann RE, et al. Contrast enhancement by lipid-based MRI contrast agents in mouse atherosclerotic plaques; a longitudinal study. Contrast media & molecular imaging. 2013; 8: 63-71. doi:10.1002/cmmi.1496.
26. Chen JW, Pham W, Weissleder R, Bogdanov A, Jr. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magnetic resonance in medicine. 2004; 52: 1021-8. doi:10.1002/mrm.20270.
27. Chen JW, Querol Sans M, Bogdanov A, Jr., Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology. 2006; 240: 473-81. doi:10.1148/radiol.2402050994.
28. Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. Journal of nuclear medicine. 2012; 53: 345-8. doi:10.2967/jnumed.111.099754.
29. Ferrante EA, Pickard JE, Rychak J, Klibanov A, Ley K. Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. Journal of controlled release. 2009; 140: 100-7. doi:10.1016/j.jconrel.2009.08.001.
30. Kaufmann BA, Carr CL, Belcik JT, Xie A, Yue Q, Chadderdon S, et al. Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease. Arteriosclerosis, thrombosis, and vascular biology. 2010; 30: 54-9. doi:10.1161/ATVBAHA.109.196386.
31. Wu J, Leong-Poi H, Bin J, Yang L, Liao Y, Liu Y, et al. Efficacy of contrast-enhanced US and magnetic microbubbles targeted to vascular cell adhesion molecule-1 for molecular imaging of atherosclerosis. Radiology. 2011; 260: 463-71. doi:10.1148/radiol.11102251.
32. Yang H, Xiong X, Zhang L, Wu C, Liu Y. Adhesion of bio-functionalized ultrasound microbubbles to endothelial cells by targeting to vascular cell adhesion molecule-1 under shear flow. International journal of nanomedicine. 2011; 6: 2043-51. doi:10.2147/IJN.S24808.
33. Wang Y, Zhou J, Zhang Y, Wang X, Chen J. Delivery of TFPI-2 using SonoVue and adenovirus results in the suppression of thrombosis and arterial re-stenosis. Experimental biology and medicine. 2010; 235: 1072-81. doi:10.1258/ebm.2010.010046.
34. Lindner JR. Molecular imaging of myocardial and vascular disorders with ultrasound. JACC Cardiovascular imaging. 2010; 3: 204-11. doi:10.1016/j.jcmg.2009.09.021.
35. Hilderbrand SA, Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Current opinion in chemical biology. 2010; 14: 71-9. doi:10.1016/j.cbpa.2009.09.029.
36. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. European radiology. 2003; 13: 195-208. doi:10.1007/s00330-002-1524-x.
37. Ntziachristos V, Razansky D. Molecular imaging by means of multispectral optoacoustic tomography (MSOT). Chemical reviews. 2010; 110: 2783-94. doi:10.1021/cr9002566.
38. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nature biotechnology. 2005; 23: 313-20. doi:10.1038/nbt1074.
39. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nature medicine. 2002; 8: 757-60. doi:10.1038/nm729.
40. Nahrendorf M, Sosnovik DE, Waterman P, Swirski FK, Pande AN, Aikawa E, et al. Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circulation research. 2007; 100: 1218-25. doi:10.1161/01.RES.0000265064.46075.31.
41. Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arteriosclerosis, thrombosis, and vascular biology. 2009; 29: 1444-51. doi:10.1161/ATVBAHA.109.193086.
42. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007; 116: 2841-50. doi:10.1161/CIRCULATIONAHA.107.732867.
43. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007; 115: 377-86. doi:10.1161/CIRCULATIONAHA.106.654913.
44. von Wallbrunn A, Holtke C, Zuhlsdorf M, Heindel W, Schafers M, Bremer C. In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography. European journal of nuclear medicine and molecular imaging. 2007; 34: 745-54. doi:10.1007/s00259-006-0269-1.
45. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008; 452: 580-9. doi:10.1038/nature06917.
46. Bremer C, Ntziachristos V, Weissleder R. Optical-based molecular imaging: contrast agents and potential medical applications. European radiology. 2003; 13: 231-43. doi:10.1007/s00330-002-1610-0.
47. Christen T, Nahrendorf M, Wildgruber M, Swirski FK, Aikawa E, Waterman P, et al. Molecular imaging of innate immune cell function in transplant rejection. Circulation. 2009; 119: 1925-32. doi:10.1161/CIRCULATIONAHA.108.796888.
48. Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, et al. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102: 14404-9. doi:10.1073/pnas.0503920102.
49. Freyer M, Ale A, Schulz RB, Zientkowska M, Ntziachristos V, Englmeier KH. Fast automatic segmentation of anatomical structures in x-ray computed tomography images to improve fluorescence molecular tomography reconstruction. Journal of biomedical optics. 2010; 15: 036006. doi:10.1117/1.3431101.
50. Ale A, Ermolayev V, Herzog E, Cohrs C, de Angelis MH, Ntziachristos V. FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray computed tomography. Nature methods. 2012; 9: 615-20. doi:10.1038/nmeth.2014.
51. Ale A, Schulz RB, Sarantopoulos A, Ntziachristos V. Imaging performance of a hybrid x-ray computed tomography-fluorescence molecular tomography system using priors. Medical physics. 2010; 37: 1976-86.
52. Schulz RB, Ale A, Sarantopoulos A, Freyer M, Soehngen E, Zientkowska M, et al. Hybrid system for simultaneous fluorescence and x-ray computed tomography. IEEE transactions on medical imaging. 2010; 29: 465-73. doi:10.1109/TMI.2009.2035310.
53. Sarantopoulos A, Themelis G, Ntziachristos V. Imaging the bio-distribution of fluorescent probes using multispectral epi-illumination cryoslicing imaging. Molecular imaging and biology. 2011; 13: 874-85. doi:10.1007/s11307-010-0416-8.
54. Razansky D, Distel M, Vinegoni C, Ma R, Perrimon N, Köster RW, et al. Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nature Photonics. 2009; 3: 412-7. doi:10.1038/nphoton.2009.98.
55. Razansky D, Harlaar NJ, Hillebrands JL, Taruttis A, Herzog E, Zeebregts CJ, et al. Multispectral optoacoustic tomography of matrix metalloproteinase activity in vulnerable human carotid plaques. Molecular imaging and biology. 2012; 14: 277-85. doi:10.1007/s11307-011-0502-6.
56. Nair A, Kuban BD, Obuchowski N, Vince DG. Assessing spectral algorithms to predict atherosclerotic plaque composition with normalized and raw intravascular ultrasound data. Ultrasound in medicine & biology. 2001; 27: 1319-31.
57. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation. 2002; 106: 2200-6.
58. Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. Journal of the American College of Cardiology. 2002; 39: 604-9.
59. Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, et al. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation. 2005; 111: 1551-5. doi:10.1161/01.CIR.0000159354.43778.69.
60. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373: 897-910. doi:10.1016/S0140-6736(09)60325-1.
61. Maehara A, Mintz GS, Weissman NJ. Advances in intravascular imaging. Circulation Cardiovascular interventions. 2009; 2: 482-90. doi:10.1161/CIRCINTERVENTIONS.109.868398.
62. Hosokawa R, Kambara N, Ohba M, Mukai T, Ogawa M, Motomura H, et al. A catheter-based intravascular radiation detector of vulnerable plaques. Journal of nuclear medicine. 2006; 47: 863-7.
63. Lederman RJ, Raylman RR, Fisher SJ, Kison PV, San H, Nabel EG, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nuclear medicine communications. 2001; 22: 747-53.
64. Strauss HW, Mari C, Patt BE, Ghazarossian V. Intravascular radiation detectors for the detection of vulnerable atheroma. Journal of the American College of Cardiology. 2006; 47: C97-100. doi:10.1016/j.jacc.2005.11.051.
65. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008; 118: 1802-9. doi:10.1161/CIRCULATIONAHA.108.785881.
66. Jaffer FA, Calfon MA, Rosenthal A, Mallas G, Razansky RN, Mauskapf A, et al. Two-dimensional intravascular near-infrared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injury. Journal of the American College of Cardiology. 2011; 57: 2516-26. doi:10.1016/j.jacc.2011.02.036.
67. Yoo H, Kim JW, Shishkov M, Namati E, Morse T, Shubochkin R, et al. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nature medicine. 2011; 17: 1680-4. doi:10.1038/nm.2555.
68. Rosenthal A, Jaffer FA, Ntziachristos V. Intravascular multispectral optoacoustic tomography of atherosclerosis: prospects and challenges. Imaging in medicine. 2012; 4: 299-310. doi:10.2217/iim.12.20.
69. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiological reviews. 2011; 91: 327-87. doi:10.1152/physrev.00047.2009.
70. Zhou J, Lee PL, Tsai CS, Lee CI, Yang TL, Chuang HS, et al. Force-specific activation of Smad1/5 regulates vascular endothelial cell cycle progression in response to disturbed flow. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109: 7770-5. doi:10.1073/pnas.1205476109.
71. Hahn C, Schwartz MA. The role of cellular adaptation to mechanical forces in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2008; 28: 2101-7. doi:10.1161/ATVBAHA.108.165951.
72. Lehoux S. Redox signalling in vascular responses to shear and stretch. Cardiovascular research. 2006; 71: 269-79. doi:10.1016/j.cardiores.2006.05.008.
73. Miyazaki T, Taketomi Y, Takimoto M, Lei XF, Arita S, Kim-Kaneyama JR, et al. m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. Circulation. 2011; 124: 2522-32. doi:10.1161/CIRCULATIONAHA.111.021675.
74. Kerwin WS, Canton G. Advanced techniques for MRI of atherosclerotic plaque. Topics in magnetic resonance imaging: TMRI. 2009; 20: 217-25. doi:10.1097/RMR.0b013e3181ea2853.
75. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature reviews Immunology. 2007; 7: 678-89. doi:10.1038/nri2156.
76. Broisat A, Riou LM, Ardisson V, Boturyn D, Dumy P, Fagret D, et al. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p. European journal of nuclear medicine and molecular imaging. 2007; 34: 830-40. doi:10.1007/s00259-006-0310-4.
77. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007; 116: 276-84. doi:10.1161/CIRCULATIONAHA.106.684738.
78. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circulation research. 2005; 96: 327-36. doi:10.1161/01.RES.0000155722.17881.dd.
79. McAteer MA, Mankia K, Ruparelia N, Jefferson A, Nugent HB, Stork LA, et al. A leukocyte-mimetic magnetic resonance imaging contrast agent homes rapidly to activated endothelium and tracks with atherosclerotic lesion macrophage content. Arteriosclerosis, thrombosis, and vascular biology. 2012; 32: 1427-35. doi:10.1161/ATVBAHA.111.241844.
80. Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo JL, et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovascular imaging. 2009; 2: 1213-22. doi:10.1016/j.jcmg.2009.04.016.
81. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008; 117: 379-87. doi:10.1161/CIRCULATIONAHA.107.741181.
82. Southworth R, Kaneda M, Chen J, Zhang L, Zhang H, Yang X, et al. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons. Nanomedicine: nanotechnology, biology, and medicine. 2009; 5: 359-67. doi:10.1016/j.nano.2008.12.002.
83. Michalska M, Machtoub L, Manthey HD, Bauer E, Herold V, Krohne G, et al. Visualization of vascular inflammation in the atherosclerotic mouse by ultrasmall superparamagnetic iron oxide vascular cell adhesion molecule-1-specific nanoparticles. Arteriosclerosis, thrombosis, and vascular biology. 2012; 32: 2350-7. doi:10.1161/ATVBAHA.112.255224.
84. Kelly KA, Nahrendorf M, Yu AM, Reynolds F, Weissleder R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Molecular imaging and biology. 2006; 8: 201-7. doi:10.1007/s11307-006-0043-6.
85. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006; 114: 1504-11. doi:10.1161/CIRCULATIONAHA.106.646380.
86. Jefferson A, Wijesurendra RS, McAteer MA, Digby JE, Douglas G, Bannister T, et al. Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: rational design through target quantification. Atherosclerosis. 2011; 219: 579-87. doi:10.1016/j.atherosclerosis.2011.07.127.
87. McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von zur Muhlen C, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arteriosclerosis, thrombosis, and vascular biology. 2008; 28: 77-83. doi:10.1161/ATVBAHA.107.145466.
88. Paulis LE, Jacobs I, van de Akker N, Geelen T, Molin D, Starmans LW, et al. Targeting of ICAM-1 on vascular endothelium under static and shear stress conditions using a liposomal Gd-based MRI contrast agent. Journal of nanobiotechnology. 2012; 10: 25. doi:10.1186/1477-3155-10-25.
89. Villanueva FS, Jankowski RJ, Klibanov S, Pina ML, Alber SM, Watkins SC, et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation. 1998; 98: 1-5.
90. Taruttis A, Wildgruber M, Kosanke K, Beziere N, Licha K, Haag R, et al. Multispectral optoacoustic tomography of myocardial infarction. Photoacoustics. 2012; doi:10.1016/j.pacs.2012.11.001.
91. Dernedde J, Rausch A, Weinhart M, Enders S, Tauber R, Licha K, et al. Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107: 19679-84. doi:10.1073/pnas.1003103107.
92. Pedersen SF, Thrysoe SA, Paaske WP, Thim T, Falk E, Ringgaard S, et al. CMR assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset. Journal of cardiovascular magnetic resonance. 2011; 13: 10. doi:10.1186/1532-429X-13-10.
93. Phinikaridou A, Andia ME, Protti A, Indermuehle A, Shah A, Smith A, et al. Noninvasive magnetic resonance imaging evaluation of endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent. Circulation. 2012; 126: 707-19. doi:10.1161/CIRCULATIONAHA.112.092098.
94. Vinegoni C, Botnaru I, Aikawa E, Calfon MA, Iwamoto Y, Folco EJ, et al. Indocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaques. Science translational medicine. 2011; 3: 84ra45. doi:10.1126/scitranslmed.3001577.
95. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nature reviews Immunology. 2006; 6: 508-19. doi:10.1038/nri1882.
96. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2009; 29: 1424-32. doi:10.1161/ATVBAHA.108.180521.
97. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nature reviews Immunology. 2005; 5: 953-64. doi:10.1038/nri1733.
98. Robbins CS, Chudnovskiy A, Rauch PJ, Figueiredo JL, Iwamoto Y, Gorbatov R, et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation. 2012; 125: 364-74. doi:10.1161/CIRCULATIONAHA.111.061986.
99. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. The Journal of clinical investigation. 2007; 117: 195-205. doi:10.1172/JCI29950.
100. Schlitt A, Heine GH, Blankenberg S, Espinola-Klein C, Dopheide JF, Bickel C, et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thrombosis and haemostasis. 2004; 92: 419-24. doi:10.1267/THRO04080419.
101. Wildgruber M, Lee H, Chudnovskiy A, Yoon TJ, Etzrodt M, Pittet MJ, et al. Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PloS one. 2009; 4: e5663. doi:10.1371/journal.pone.0005663.
102. Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. Journal of the American College of Cardiology. 2009; 54: 130-8. doi:10.1016/j.jacc.2009.04.021.
103. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, JM UK-I, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. Journal of the American College of Cardiology. 2009; 53: 2039-50. doi:10.1016/j.jacc.2009.03.018.
104. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. The Journal of experimental medicine. 2007; 204: 3037-47. doi:10.1084/jem.20070885.
105. Settles M, Etzrodt M, Kosanke K, Schiemann M, Zimmermann A, Meier R, et al. Different capacity of monocyte subsets to phagocytose iron-oxide nanoparticles. PloS one. 2011; 6: e25197. doi:10.1371/journal.pone.0025197.
106. Makowski MR, Varma G, Wiethoff AJ, Smith A, Mattock K, Jansen CH, et al. Noninvasive assessment of atherosclerotic plaque progression in ApoE-/-mice using susceptibility gradient mapping. Circulation Cardiovascular imaging. 2011; 4: 295-303. doi:10.1161/CIRCIMAGING.110.957209.
107. Metz S, Beer AJ, Settles M, Pelisek J, Botnar RM, Rummeny EJ, et al. Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability. The international journal of cardiovascular imaging. 2011; 27: 901-12. doi:10.1007/s10554-010-9736-7.
108. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Investigative radiology. 2000; 35: 460-71.
109. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nature biotechnology. 2005; 23: 1407-13. doi:10.1038/nbt1154.
110. Kircher MF, Grimm J, Swirski FK, Libby P, Gerszten RE, Allport JR, et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation. 2008; 117: 388-95. doi:10.1161/CIRCULATIONAHA.107.719765.
111. Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JG, Vucic E, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magnetic resonance in medicine. 2007; 58: 1164-70. doi:10.1002/mrm.21315.
112. te Boekhorst BC, Bovens SM, Hellings WE, van der Kraak PH, van de Kolk KW, Vink A, et al. Molecular MRI of murine atherosclerotic plaque targeting NGAL: a protein associated with unstable human plaque characteristics. Cardiovascular research. 2011; 89: 680-8. doi:10.1093/cvr/cvq340.
113. te Boekhorst BC, Bovens SM, Rodrigues-Feo J, Sanders HM, van de Kolk CW, de Kroon AI, et al. Characterization and in vitro and in vivo testing of CB2-receptor- and NGAL-targeted paramagnetic micelles for molecular MRI of vulnerable atherosclerotic plaque. Molecular imaging and biology. 2010; 12: 635-51. doi:10.1007/s11307-010-0323-z.
114. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circulation Cardiovascular imaging. 2009; 2: 331-8. doi:10.1161/CIRCIMAGING.108.846865.
115. Saraste A, Laitinen I, Weidl E, Wildgruber M, Weber AW, Nekolla SG, et al. Diet intervention reduces uptake of alphavbeta3 integrin-targeted PET tracer 18F-galacto-RGD in mouse atherosclerotic plaques. Journal of nuclear cardiology. 2012; 19: 775-84. doi:10.1007/s12350-012-9554-5.
116. Burtea C, Laurent S, Murariu O, Rattat D, Toubeau G, Verbruggen A, et al. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovascular research. 2008; 78: 148-57. doi:10.1093/cvr/cvm115.
117. Calcagno C, Cornily JC, Hyafil F, Rudd JH, Briley-Saebo KC, Mani V, et al. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arteriosclerosis, thrombosis, and vascular biology. 2008; 28: 1311-7. doi:10.1161/ATVBAHA.108.166173.
118. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708-11.
119. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009; 207: 139-43. doi:10.1016/j.atherosclerosis.2009.04.023.
120. Tu C, Ng TS, Sohi HK, Palko HA, House A, Jacobs RE, et al. Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials. 2011; 32: 7209-16. doi:10.1016/j.biomaterials.2011.06.026.
121. Bucerius J, Mani V, Moncrieff C, Rudd JH, Machac J, Fuster V, et al. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. Journal of the American College of Cardiology. 2012; 59: 2080-8. doi:10.1016/j.jacc.2011.11.069.
122. Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Annals of neurology. 2012; 71: 709-18. doi:10.1002/ana.23553.
123. Moustafa RR, Izquierdo-Garcia D, Fryer TD, Graves MJ, Rudd JH, Gillard JH, et al. Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot study. Circulation Cardiovascular imaging. 2010; 3: 536-41. doi:10.1161/CIRCIMAGING.110.938225.
124. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011; 378: 1547-59. doi:10.1016/S0140-6736(11)61383-4.
125. Pedersen SF, Graebe M, Fisker Hag AM, Hojgaard L, Sillesen H, Kjaer A. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nuclear medicine communications. 2010; 31: 423-9. doi:10.1097/MNM.0b013e32833767e0.
126. Myers KS, Rudd JH, Hailman EP, Bolognese JA, Burke J, Pinto CA, et al. Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. JACC Cardiovascular imaging. 2012; 5: 38-45. doi:10.1016/j.jcmg.2011.08.019.
127. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. Journal of the American College of Cardiology. 2011; 58: 603-14. doi:10.1016/j.jacc.2011.03.044.
128. Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation. 2008; 117: 3206-15. doi:10.1161/CIRCULATIONAHA.107.757120.
129. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. The American journal of pathology. 2001; 158: 879-91. doi:10.1016/S0002-9440(10)64036-9.
130. Nahrendorf M, Sosnovik D, Chen JW, Panizzi P, Figueiredo JL, Aikawa E, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation. 2008; 117: 1153-60. doi:10.1161/CIRCULATIONAHA.107.756510.
131. Swirski FK, Wildgruber M, Ueno T, Figueiredo JL, Panizzi P, Iwamoto Y, et al. Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. The Journal of clinical investigation. 2010; 120: 2627-34. doi:10.1172/JCI42304.
132. Ronald JA, Chen JW, Chen Y, Hamilton AM, Rodriguez E, Reynolds F, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation. 2009; 120: 592-9. doi:10.1161/CIRCULATIONAHA.108.813998.
133. Panizzi P, Nahrendorf M, Wildgruber M, Waterman P, Figueiredo JL, Aikawa E, et al. Oxazine conjugated nanoparticle detects in vivo hypochlorous acid and peroxynitrite generation. Journal of the American Chemical Society. 2009; 131: 15739-44. doi:10.1021/ja903922u.
134. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-74. doi:10.1038/nature01323.
135. Haider N, Hartung D, Fujimoto S, Petrov A, Kolodgie FD, Virmani R, et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. Journal of nuclear cardiology. 2009; 16: 753-62. doi:10.1007/s12350-009-9107-8.
136. Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. Journal of nuclear medicine. 2011; 52: 1795-802. doi:10.2967/jnumed.111.092379.
137. Quillard T, Croce K, Jaffer FA, Weissleder R, Libby P. Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo. Thrombosis and haemostasis. 2011; 105: 828-36. doi:10.1160/TH10-09-0589.
138. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006; 114: 55-62. doi:10.1161/CIRCULATIONAHA.106.619056.
139. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002; 105: 2766-71.
140. Kim DE, Kim JY, Schellingerhout D, Shon SM, Jeong SW, Kim EJ, et al. Molecular imaging of cathepsin B proteolytic enzyme activity reflects the inflammatory component of atherosclerotic pathology and can quantitatively demonstrate the antiatherosclerotic therapeutic effects of atorvastatin and glucosamine. Molecular imaging. 2009; 8: 291-301.
141. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation. 2007; 115: 2292-8. doi:10.1161/CIRCULATIONAHA.106.660340.
142. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation. 2009; 119: 1785-94. doi:10.1161/CIRCULATIONAHA.108.827972.
143. Amirbekian V, Aguinaldo JG, Amirbekian S, Hyafil F, Vucic E, Sirol M, et al. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology. 2009; 251: 429-38. doi:10.1148/radiol.2511080539.
144. Hyafil F, Vucic E, Cornily JC, Sharma R, Amirbekian V, Blackwell F, et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. European heart journal. 2011; 32: 1561-71. doi:10.1093/eurheartj/ehq413.
145. Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxidants & redox signaling. 2009; 11: 2333-9. doi:10.1089/ARS.2009.2469.
146. Laufer EM, Reutelingsperger CP, Narula J, Hofstra L. Annexin A5: an imaging biomarker of cardiovascular risk. Basic research in cardiology. 2008; 103: 95-104. doi:10.1007/s00395-008-0701-8.
147. Laufer EM, Winkens HM, Corsten MF, Reutelingsperger CP, Narula J, Hofstra L. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled Annexin A5. The quarterly journal of nuclear medicine and molecular imaging. 2009; 53: 26-34.
148. Ishino S, Kuge Y, Takai N, Tamaki N, Strauss HW, Blankenberg FG, et al. 99mTc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. European journal of nuclear medicine and molecular imaging. 2007; 34: 889-99. doi:10.1007/s00259-006-0289-x.
149. Isobe S, Tsimikas S, Zhou J, Fujimoto S, Sarai M, Branks MJ, et al. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2006; 47: 1497-505.
150. Johnson LL, Schofield L, Donahay T, Narula N, Narula J. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. Journal of nuclear medicine. 2005; 46: 1186-93.
151. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. The New England journal of medicine. 2004; 350: 1472-3. doi:10.1056/NEJM200404013501425.
152. Sarai M, Hartung D, Petrov A, Zhou J, Narula N, Hofstra L, et al. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging. Journal of the American College of Cardiology. 2007; 50: 2305-12. doi:10.1016/j.jacc.2007.08.044.
153. van Tilborg GA, Vucic E, Strijkers GJ, Cormode DP, Mani V, Skajaa T, et al. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjugate chemistry. 2010; 21: 1794-803. doi:10.1021/bc100091q.
154. Sosnovik DE, Garanger E, Aikawa E, Nahrendorf M, Figuiredo JL, Dai G, et al. Molecular MRI of cardiomyocyte apoptosis with simultaneous delayed-enhancement MRI distinguishes apoptotic and necrotic myocytes in vivo: potential for midmyocardial salvage in acute ischemia. Circulation Cardiovascular imaging. 2009; 2: 460-7. doi:10.1161/CIRCIMAGING.109.859678.
155. Sosnovik DE, Nahrendorf M, Panizzi P, Matsui T, Aikawa E, Dai G, et al. Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure. Circulation Cardiovascular imaging. 2009; 2: 468-75. doi:10.1161/CIRCIMAGING.109.863779.
156. Barkhausen J, Ebert W, Heyer C, Debatin JF, Weinmann HJ. Detection of atherosclerotic plaque with Gadofluorine-enhanced magnetic resonance imaging. Circulation. 2003; 108: 605-9. doi:10.1161/01.CIR.0000079099.36306.10.
157. Meding J, Urich M, Licha K, Reinhardt M, Misselwitz B, Fayad ZA, et al. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Contrast media & molecular imaging. 2007; 2: 120-9. doi:10.1002/cmmi.137.
158. Ronald JA, Chen Y, Belisle AJ, Hamilton AM, Rogers KA, Hegele RA, et al. Comparison of gadofluorine-M and Gd-DTPA for noninvasive staging of atherosclerotic plaque stability using MRI. Circulation Cardiovascular imaging. 2009; 2: 226-34. doi:10.1161/CIRCIMAGING.108.826826.
159. Makowski MR, Wiethoff AJ, Blume U, Cuello F, Warley A, Jansen CH, et al. Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent. Nature medicine. 2011; 17: 383-8. doi:10.1038/nm.2310.
160. von Bary C, Makowski M, Preissel A, Keithahn A, Warley A, Spuentrup E, et al. MRI of coronary wall remodeling in a swine model of coronary injury using an elastin-binding contrast agent. Circulation Cardiovascular imaging. 2011; 4: 147-55. doi:10.1161/CIRCIMAGING.109.895607.
161. Phinikaridou A, Andia ME, Shah AM, Botnar R. Advances in Molecular Imaging of Atherosclerosis and Myocardial Infarction: Shedding New Light on In vivo Cardiovascular Biology. American journal of physiology Heart and circulatory physiology. 2012. doi:10.1152/ajpheart.00583.2012.
162. Sanders HM, Strijkers GJ, Mulder WJ, Huinink HP, Erich SJ, Adan OC, et al. Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes. Contrast media & molecular imaging. 2009; 4: 81-8. doi:10.1002/cmmi.266.
163. Alexopoulos N, Raggi P. Calcification in atherosclerosis. Nature reviews Cardiology. 2009; 6: 681-8. doi:10.1038/nrcardio.2009.165.
164. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 2012; 125: 76-86. doi:10.1161/CIRCULATIONAHA.111.051052.
165. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. European heart journal. 2010; 31: 1975-84. doi:10.1093/eurheartj/ehq237.
166. Motoyama S, Kondo T, Sarai M, Sugiura A, Harigaya H, Sato T, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. Journal of the American College of Cardiology. 2007; 50: 319-26. doi:10.1016/j.jacc.2007.03.044.
167. Duerschmied D, Meissner M, Peter K, Neudorfer I, Roming F, Zirlik A, et al. Molecular magnetic resonance imaging allows the detection of activated platelets in a new mouse model of coronary artery thrombosis. Investigative radiology. 2011; 46: 618-23. doi:10.1097/RLI.0b013e31821e62fb.
168. von zur Muhlen C, Peter K, Ali ZA, Schneider JE, McAteer MA, Neubauer S, et al. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. Journal of vascular research. 2009; 46: 6-14. doi:10.1159/000135660.
169. Botnar RM, Buecker A, Wiethoff AJ, Parsons EC, Jr., Katoh M, Katsimaglis G, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004; 110: 1463-6. doi:10.1161/01.CIR.0000134960.31304.87.
170. Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004; 109: 2023-9. doi:10.1161/01.CIR.0000127034.50006.C0.
171. Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC, Jr., Botnar RM, et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation. 2005; 111: 1377-82. doi:10.1161/01.CIR.0000158478.29668.9B.
172. Spuentrup E, Fausten B, Kinzel S, Wiethoff AJ, Botnar RM, Graham PB, et al. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation. 2005; 112: 396-9. doi:10.1161/CIRCULATIONAHA.104.529941.
173. Katoh M, Haage P, Wiethoff AJ, Gunther RW, Bucker A, Tacke J, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Investigative radiology. 2009; 44: 146-50. doi:10.1097/RLI.0b013e318195886d.
174. Spuentrup E, Botnar RM, Wiethoff AJ, Ibrahim T, Kelle S, Katoh M, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. European radiology. 2008; 18: 1995-2005. doi:10.1007/s00330-008-0965-2.
175. Vymazal J, Spuentrup E, Cardenas-Molina G, Wiethoff AJ, Hartmann MG, Caravan P, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Investigative radiology. 2009; 44: 697-704. doi:10.1097/RLI.0b013e3181b092a7.
176. Uppal R, Catana C, Ay I, Benner T, Sorensen AG, Caravan P. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe--feasibility study in rat model. Radiology. 2011; 258: 812-20. doi:10.1148/radiol.10100881.
177. Makowski MR, Forbes SC, Blume U, Warley A, Jansen CH, Schuster A, et al. In vivo assessment of intraplaque and endothelial fibrin in ApoE(-/-) mice by molecular MRI. Atherosclerosis. 2012; 222: 43-9. doi:10.1016/j.atherosclerosis.2012.01.008.
178. Jaffer FA, Tung CH, Wykrzykowska JJ, Ho NH, Houng AK, Reed GL, et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation. 2004; 110: 170-6. doi:10.1161/01.CIR.0000134484.11052.44.
179. Miserus RJ, Herias MV, Prinzen L, Lobbes MB, Van Suylen RJ, Dirksen A, et al. Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovascular imaging. 2009; 2: 987-96. doi:10.1016/j.jcmg.2009.03.015.
180. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. Journal of the American College of Cardiology. 2005; 46: 1209-18. doi:10.1016/j.jacc.2005.03.075.
181. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. Journal of the American College of Cardiology. 2005; 46: 937-54. doi:10.1016/j.jacc.2005.03.074.
182. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nature medicine. 2011; 17: 1315-9. doi:10.1038/nm.2472.
183. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. Journal of nuclear medicine. 2009; 50: 563-8. doi:10.2967/jnumed.108.055616.